NCT00515762

Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling

Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling (ELASTO-GEL CAPS)in Breast Cancer Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Hospital San Carlos, Madrid · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens.

Detailed description

Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. Docetaxel is toxic to skin and skin annexes and can produce nail toxicity and persistent alopecia. Nail toxicity has been successfully prevented by means of hypothermic gloves and slippers (Elasto-gel, Southwest Technologies, Inc, North Kansas City, MO). This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens.

Conditions

• Alopecia
• Breast Cancer

Interventions

Type	Name	Description
DEVICE	elasto-gel cap	scalp cooling cap

Timeline

• Start date: 2007-05-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2007-08-14
• Last updated: 2011-08-09

Locations

1 site across 1 country: Spain